title: Chemoprevention of colorectal cancer.
abstract: Colorectal cancer has become one of the most prevalent malignant diseases for both men and women. Patients with inflammatory bowel diseases or certain inherited cancer syndromes are at high risk of developing colorectal cancer and have naturally the highest need for cancer prevention. In familial adenomatous polyposis (FAP) and Lynch syndrome, most of the underlying germline mutations can be detected by DNA sequencing, and medical counselling of affected individuals involves both surveillance tests and chemopreventive measures. However, as the mechanisms leading to colorectal cancer differ in these high-risk groups, the molecular action of chemopreventive drugs needs to be adjusted to the certain pathway of carcinogenesis. In the last decades, a number of drugs have been tested, including sulindac, aspirin, celecoxib, and mesalazine, but some of them are still controversially discussed. This review summarizes the advances and current standards of colorectal cancer prevention in patients with inflammatory bowel disease, FAP and Lynch syndrome.
authors.affiliation: Christian Doppler Laboratory for Molecular Cancer Chemoprevention, Division of Gastroenterology and Hepatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.
authors.forename: Michaela
authors.initials: M
authors.lastname: Lang
authors.forename: Christoph
authors.initials: C
authors.lastname: Gasche
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018890:Chemoprevention; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000517:prevention & control*; D019587:Dietary Supplements; D004359:Drug Therapy, Combination; D006801:Humans; D064209:Phytochemicals / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D064209:Phytochemicals